Elahe A Mostaghel

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi request reprint The basic biochemistry and molecular events of hormone therapy
    Elahe A Mostaghel
    Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA 98109, USA
    Curr Urol Rep 8:224-32. 2007
  2. pmc Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants
    Elahe A Mostaghel
    Division of Clinical Research and Human Biology, Fred Hutchinson Cancer Research Center Department of Medicine, University of Washington, Seattle, Washington, USA
    Clin Cancer Res 17:5913-25. 2011
  3. pmc Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications
    Elahe A Mostaghel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Best Pract Res Clin Endocrinol Metab 22:243-58. 2008
  4. pmc Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention
    Elahe A Mostaghel
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D4 100, Seattle, WA 91809, USA
    Cancer Res 70:1286-95. 2010
  5. pmc Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth
    R Bruce Montgomery
    Department of Medicine, University of Washington School of Medicine, Weattle, WA, USA
    Cancer Res 68:4447-54. 2008
  6. pmc Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial
    Elahe A Mostaghel
    Division of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Clin Endocrinol Metab 97:2809-17. 2012
  7. pmc Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
    Shihua Sun
    Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98104, USA
    J Clin Invest 120:2715-30. 2010
  8. pmc Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial
    Stephanie T Page
    Division of Metabolism, Endocrinology, and Nutrition, University of Washington School of Medicine, Box 357138, 1959 NE Pacific Street, Seattle, Washington 98195, USA
    J Clin Endocrinol Metab 96:430-7. 2011
  9. ncbi request reprint Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer
    Elahe A Mostaghel
    Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA
    Cancer Res 67:5033-41. 2007
  10. doi request reprint Testosterone regulates tight junction proteins and influences prostatic autoimmune responses
    Jing Meng
    Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, D4 100, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    Horm Cancer 2:145-56. 2011

Collaborators

Detail Information

Publications27

  1. ncbi request reprint The basic biochemistry and molecular events of hormone therapy
    Elahe A Mostaghel
    Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA 98109, USA
    Curr Urol Rep 8:224-32. 2007
    ....
  2. pmc Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants
    Elahe A Mostaghel
    Division of Clinical Research and Human Biology, Fred Hutchinson Cancer Research Center Department of Medicine, University of Washington, Seattle, Washington, USA
    Clin Cancer Res 17:5913-25. 2011
    ..The effectiveness of abiraterone in reducing tumor androgens is not known, nor have mechanisms contributing to abiraterone resistance been established...
  3. pmc Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications
    Elahe A Mostaghel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Best Pract Res Clin Endocrinol Metab 22:243-58. 2008
    ....
  4. pmc Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention
    Elahe A Mostaghel
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D4 100, Seattle, WA 91809, USA
    Cancer Res 70:1286-95. 2010
    ..Our findings suggest that AR levels may predict the chemopreventive efficacy of SRD5A inhibitors...
  5. pmc Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth
    R Bruce Montgomery
    Department of Medicine, University of Washington School of Medicine, Weattle, WA, USA
    Cancer Res 68:4447-54. 2008
    ..Maximal therapeutic efficacy in the treatment of castration-resistant prostate cancer will require novel agents capable of inhibiting intracrine steroidogenic pathways within the prostate tumor microenvironment...
  6. pmc Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial
    Elahe A Mostaghel
    Division of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Clin Endocrinol Metab 97:2809-17. 2012
    ..Male hormonal contraception (MHC) combines hypothalamic-pituitary-gonadal axis blockade with exogenous androgen delivery to maintain extragonadal androgen end-organ effects. Concern exists that MHC may adversely impact prostate health...
  7. pmc Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
    Shihua Sun
    Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98104, USA
    J Clin Invest 120:2715-30. 2010
    ....
  8. pmc Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial
    Stephanie T Page
    Division of Metabolism, Endocrinology, and Nutrition, University of Washington School of Medicine, Box 357138, 1959 NE Pacific Street, Seattle, Washington 98195, USA
    J Clin Endocrinol Metab 96:430-7. 2011
    ..Exogenous androgens raise serum DHT concentrations, but their effects on the prostate are not clear...
  9. ncbi request reprint Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer
    Elahe A Mostaghel
    Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA
    Cancer Res 67:5033-41. 2007
    ..Optimal clinical efficacy will require testing of novel approaches targeting complete suppression of systemic and intracrine contributions to the prostatic androgen microenvironment...
  10. doi request reprint Testosterone regulates tight junction proteins and influences prostatic autoimmune responses
    Jing Meng
    Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, D4 100, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    Horm Cancer 2:145-56. 2011
    ....
  11. pmc Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes
    Jonathan L Wright
    Department of Urology, University of Washington, Seattle, WA, USA
    Cancer Epidemiol Biomarkers Prev 20:619-27. 2011
    ....
  12. pmc Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease
    Elahe A Mostaghel
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Urol Oncol 27:251-7. 2009
    ..Targeting these metabolic enzymes either individually or using combinations of agents to inhibit testicular, adrenal, and intracrine sources may provide enhanced clinical responses in the setting of both localized and metastatic disease...
  13. pmc Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors
    Elahe A Mostaghel
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 7:e30062. 2012
    ....
  14. pmc Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
    William P Harris
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA 98195, USA
    Nat Clin Pract Urol 6:76-85. 2009
    ....
  15. pmc Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors
    Changmeng Cai
    Hematology Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 71:6503-13. 2011
    ..Together, our results indicate that CRPCs resistant to CYP17A1 inhibition may remain steroid dependent and therefore responsive to therapies that can further suppress de novo intratumoral steroid synthesis...
  16. ncbi request reprint Analysis of testosterone and dihydrotestosterone from biological fluids as the oxime derivatives using high-performance liquid chromatography/tandem mass spectrometry
    Thomas F Kalhorn
    Mass Spectrometry Center, Department of Medicinal Chemistry, University of Washington, Seattle, WA 98195 7610, USA
    Rapid Commun Mass Spectrom 21:3200-6. 2007
    ..Given its high reproducibility, sensitivity, and relative simplicity, this assay should be of use in determining androgen levels in biospecimens, particularly in settings where sample quantity or steroid concentration are low...
  17. pmc Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis
    Elahe A Mostaghel
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America Department of Medicine, University of Washington School of Medicine, Seattle, Washington, United States of America
    PLoS ONE 9:e111545. 2014
    ..We hypothesized that the efficacy of inhibiting DHT ligand synthesis would associate with intra-tumoral androgen ratios indicative of relative dependence on DHT-mediated growth...
  18. pmc Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer
    Ziyang Yu
    Authors Affiliations Hematology Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts and Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington
    Clin Cancer Res 20:1590-600. 2014
    ....
  19. pmc New hormonal therapies for castration-resistant prostate cancer
    Elahe A Mostaghel
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Endocrinol Metab Clin North Am 40:625-42, x. 2011
    ..This article reviews AR and ligand-dependent mechanisms underlying CRPC progression and the status of novel hormonal therapies targeting the AR axis that are currently in clinical and preclinical development...
  20. pmc Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study
    Mary Ellen Taplin
    Mary Ellen Taplin, Massimo Loda, Rosina T Lis, Wanling Xie, Zhenyang Jiang, and Philip W Kantoff, Dana Farber Cancer Institute, Harvard Medical School Glenn J Bubley, Huihui Ye, and Steven P Balk, Beth Israel Deaconess Medical Center Jerome P Richie, Massimo Loda, and Rosina T Lis, Brigham and Women s Hospital, Boston, MA Bruce Montgomery, Bruce L Dalkin, Lawrence D True, and Alvin M Matsumoto, University of Washington Brett T Marck and Alvin M Matsumoto, Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System Elahe A Mostaghel and Peter S Nelson, Fred Hutchinson Cancer Research Center, Seattle, WA Christopher J Logothetis, John W Davis, and Patricia Troncoso, University of Texas MD Anderson Cancer Center, Houston, TX Martin G Sanda, Emory University School of Medicine, Atlanta, GA Massimo Loda, King s College London, London, United Kingdom Trevor M Penning and Daniel Tamae
    J Clin Oncol 32:3705-15. 2014
    ..The possibility that greater androgen suppression in patients with localized high-risk PCa will result in improved clinical outcomes makes paramount the reassessment of neoadjuvant ADT with more robust androgen suppression...
  21. pmc Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit
    Elahe A Mostaghel
    Authors Affiliations Division of Clinical Research, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, Washington
    Clin Cancer Res 20:791-8. 2014
    ....
  22. pmc Minireview: SLCO and ABC transporters: a role for steroid transport in prostate cancer progression
    Eunpi Cho
    School of Medicine E C, R B M, University of Washington, Seattle, Washington 98195 and Division of Clinical Research E A M, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109
    Endocrinology 155:4124-32. 2014
    ....
  23. pmc Practical guide to the use of abiraterone in castration resistant prostate cancer
    Elahe A Mostaghel
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Can J Urol 21:57-63. 2014
    ..Abiraterone is the first new drug to enter clinical practice in a series of novel agents designed to potently target adrenal and tumor androgen production...
  24. pmc Glucocorticoids and prostate cancer treatment: friend or foe?
    Bruce Montgomery
    Department of Medicine, University of Washington, Seattle, Washington, USA
    Asian J Androl 16:354-8. 2014
    ....
  25. ncbi request reprint Persistent intraprostatic androgen concentrations after medical castration in healthy men
    Stephanie T Page
    University of Washington Medical Center, Division of Metabolism, Endocrinology and Nutrition, Box 357138, 1959 NE Pacific, Seattle, WA 98195
    J Clin Endocrinol Metab 91:3850-6. 2006
    ..Studies of men with prostate cancer have suggested that prostatic androgens are preserved in the setting of castration. Tissue androgens might stimulate prostate growth, producing adverse clinical consequences...
  26. doi request reprint Prostate tissue androgens: history and current clinical relevance
    Leonard S Marks
    Department of Urology, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, California, USA
    Urology 72:247-54. 2008
    ..Determination of prostate tissue androgens may soon transition from research tool to clinical test...